Uromigos Live 2024 Radioligands Part 1: VISION and PSMAFore Discussion

A live discussion on radioligands was moderated by Brian Rini, MD, of Vanderbilt-Ingram Cancer Center, and featured panelists Karen Autio, MD, and Michael Morris, MD, of Memorial Sloan Kettering Cancer Center; Gary T. Smith, MD, of Vanderbilt University Medical Center; and Tanya Dorff, MD, of City of Hope. In part one, the panelists review the latest developments in prostate cancer, with a focus on data presented at the 2024 European Society for Medical Oncology Congress, including SPLASH results, which explored the efficacy of lutetium-177-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer.